Toledano Miranda Jayne Acquires Shares in Journey Medical Corporation
Insider Toledano Miranda Jayne purchased 10,000 shares of Journey Medical Corporation.
Key Points
- On June 25, 2026, Toledano Miranda Jayne acquired 10,000 shares of Journey Medical Corporation, trading on the NasdaqCM under the ticker DERM.
- Journey Medical Corporation, with a market cap of approximately $182.3 million, saw its shares trading near $6.62 on Tuesday.
- Multiple insiders, including CFO Joseph Benesch, have recently acquired shares, while analysts maintain a strong buy consensus with a target price of $13.5.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Toledano Miranda Jayne recently purchased 10,000 shares of Journey Medical Corporation (NASDAQ: DERM) on June 25, 2026. This insider action comes amidst a series of similar transactions by other insiders at the company.
Insider Buying and Selling at Journey Medical Corporation
On June 25, 2026, several insiders, including Toledano Miranda Jayne, Justin Adam Smith, Michael Cooper Pearce, Neil Herskowitz, Lindsay MD Rosenwald, and CFO Joseph Benesch, acquired 10,000 shares each. These transactions were not part of any pre-planned trading programs, indicating a direct purchase of shares.
Journey Medical Corporation Stock Down 11.4%
Shares of Journey Medical Corporation traded near $6.62 on Tuesday. The company, operating in the healthcare sector, has a market cap of about $182.3 million. Despite not being profitable, its forward P/E ratio is listed as -110.3. The stock's 52-week range spans from $4.31 to $9.56, with a 50-day moving average of $5.79 and a 200-day moving average of $7.12. The company's current ratio stands at 1.72, with a quick ratio of 1.38 and a debt-to-equity ratio of 82.6.
$DERM stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have shown optimism towards Journey Medical Corporation, with HC Wainwright & Co. reiterating a buy rating and a $13.0 price target on March 26, 2026. The consensus among analysts is a strong buy, with an average target price of $13.5 based on four analyst opinions.
About Journey Medical Corporation
Journey Medical Corporation is a Scottsdale, Arizona-based pharmaceutical company specializing in dermatological products. Founded in 2014, it focuses on developing and commercializing treatments for skin conditions. Its products include Qbrexza for hyperhidrosis, Accutane for severe acne, and Amzeeq for acne vulgaris, among others. Led by CEO Claude Maraoui, the company employs 58 people.
Bottom Line
The insider buying activity at Journey Medical Corporation, including the recent acquisition by Toledano Miranda Jayne, suggests confidence among its executives. Journey Medical operates in the competitive field of dermatological pharmaceuticals, and its stock has seen varied analyst ratings. Investors often track insider transactions for potential insights, but it's important to note these actions do not guarantee future performance.
Get Journey Medical Corporation alerts
New 13F filings, insider trades, and analyst moves on $DERM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.